Complete Pathway Refactoring and Combinatorial Biosynthesis of Anthracyclines for Modulation of Histone Eviction and DNA Damage Bioactivities
Open Access
- 23 September 2026
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 65 (45) , e1050964
Abstract
Anthracyclines including doxorubicin are cornerstone chemotherapeutic agents with high cytotoxic potency, but their use in cancer treatment is limited by irreversible dose‐dependent cardiotoxicity. Recent investigations indicate that cardiotoxicity‐free anthracyclines may be achieved through uncoupling DNA damage from chromatin damage. However, semi‐synthetic derivatization is complicated by anthracycline structural complexity. Here, we report a modular synthetic biology platform for the complete refactoring and combinatorial biosynthesis of anthracyclines in Streptomyces coelicolor M1152Δ matAB . Using standardized synthetic DNA parts, we refactored three full biosynthetic pathways of nogalamycin (38 genes), doxorubicin (31 genes), and aclacinomycin (31 genes). The pathways were organized into four functional modules (aglycone biosynthesis, TDP‐carbohydrate formation, glycosylation, and tailoring reactions) to facilitate efficient reconstruction. The modular design facilitated streamlined combinatorial biosynthesis yielding 16 derivatives, including 13 novel analogs. Bioactivity profiling across human cancer cell lines identified six potent congeners. Their cytotoxicity correlated with in vitro DNA binding affinities. Two hit molecules harbored desired bioactivity profiles promoting histone eviction at a faster rate than doxorubicin, without causing DNA double strand breaks. Our approach highlights the power of synthetic biology in rational natural product engineering and provides a scalable strategy for exploring new and improved anthracycline anti‐cancer agents.Keywords
Funding Information
- National Science Foundation (ENG‐2015951)
- National Science Foundation (ENG‐2321976)
- National Institute of Food and Agriculture (2023‐38821‐39584)
- National Center for Advancing Translational Sciences (UL1TR000117)
- National Center for Advancing Translational Sciences (UL1TR001998)
- Research Council of Finland (340013)
- Research Council of Finland (354998)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Syöpäsäätiö
- Novo Nordisk Fonden (NNF25OC0105790)
This publication has 66 references indexed in Scilit:
- Rationale and Design of RESILIENCE: A Prospective Randomized Clinical Trial Evaluating Remote Ischaemic Conditioning for the Prevention of Anthracycline CardiotoxicityEuropean Journal of Heart Failure, 2024
- Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010JAMA Network Open, 2023
- A BioBricks toolbox for metabolic engineering of the tetracenomycin pathwayBiotechnology Journal, 2021
- The Rieske Oxygenase SnoT Catalyzes 2′′‐Hydroxylation of l‐Rhodosamine in Nogalamycin BiosynthesisChemBioChem, 2020
- Antitumour Anthracyclines: Progress and PerspectivesChemMedChem, 2020
- Identification of Late‐Stage Glycosylation Steps in the Biosynthetic Pathway of the Anthracycline NogalamycinChemBioChem, 2011
- Biosynthetic Anthracycline Variants2008
- Congestive heart failure in patients treated with doxorubicinCancer, 2003
- Combinatorial Biosynthesis–An Approach in the Near Future?Angewandte Chemie International Edition, 1995
- Adriamycin, 14‐hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesiusBiotechnology and Bioengineering, 1969